{"transactions":[{"id":723052,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":22268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 31, 2025."}],"balance_after":30000,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":22268},"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723051,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":false,"shares":7732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 31, 2025."}],"balance_after":52268,"derivative":{"exercise_price":1.23,"exercise_date":"2025-12-31","expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":7732},"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723050,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":22268,"price":5.04,"value":112230.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723049,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":22268,"price":1.23,"value":27389.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"}],"balance_after":28768,"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723048,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":7732,"price":5,"value":38660.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":723047,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:24:12.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":true,"shares":7732,"price":1.23,"value":9510.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025"}],"balance_after":14232,"source":{"system":"sec-edgar","filing":"0001133416-26-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000061/form4.xml","form_type":"4"}},{"id":934502,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:46:52.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000028","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000028/form4.xml","form_type":"4"}},{"id":962314,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-19T21:05:11.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 31, 2022.."}],"balance_after":0,"derivative":{"exercise_price":1.98,"exercise_date":"2022-12-31","expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001133416-25-000067","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000067/form4.xml","form_type":"4"}},{"id":962313,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-19T21:05:11.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":4706,"price":7.038,"value":33120.828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.11 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001133416-25-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000067/form4.xml","form_type":"4"}},{"id":962312,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-19T21:05:11.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":19793,"price":7.038,"value":139303.134,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $7.11 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000067/form4.xml","form_type":"4"}},{"id":962311,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-19T21:05:11.000Z","date":"2025-12-17","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":1.98,"value":39600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":31206,"source":{"system":"sec-edgar","filing":"0001133416-25-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000067/form4.xml","form_type":"4"}},{"id":968014,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":false,"shares":8417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018."}],"balance_after":0,"derivative":{"exercise_price":4.16,"exercise_date":"2018-12-31","expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":8417},"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968013,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":false,"shares":19793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018."}],"balance_after":53417,"derivative":{"exercise_price":4.16,"exercise_date":"2018-12-31","expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":16790},"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968012,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":8417,"price":6.3,"value":53027.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968011,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stok","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":true,"shares":8417,"price":4.16,"value":35014.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":19623,"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968010,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-12","kind":"sale","planned":true,"acquired":false,"shares":19793,"price":6.274,"value":124181.282,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":968009,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T21:22:54.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":true,"shares":19793,"price":4.16,"value":82338.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":30999,"source":{"system":"sec-edgar","filing":"0001133416-25-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000064/form4.xml","form_type":"4"}},{"id":974841,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-09","kind":"exercise","planned":true,"acquired":false,"shares":16790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018."}],"balance_after":73210,"derivative":{"exercise_price":4.16,"exercise_date":"2018-12-31","expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":16790},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974840,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vested 100% on December 31, 2023."}],"balance_after":20000,"derivative":{"exercise_price":1.11,"exercise_date":"2023-12-31","expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974839,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested 100% on December 31, 2024."}],"balance_after":35000,"derivative":{"exercise_price":2.11,"exercise_date":"2024-12-31","expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974838,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested 100% on December 31, 2024."}],"balance_after":25000,"derivative":{"exercise_price":1.72,"exercise_date":"2024-12-31","expiration_date":"2034-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974837,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested 100% on December 31, 2022."}],"balance_after":20000,"derivative":{"exercise_price":1.98,"exercise_date":"2022-12-31","expiration_date":"2032-01-24","underlying":"Common stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974836,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested 100% on December 31, 2021."}],"balance_after":20000,"derivative":{"exercise_price":2.11,"exercise_date":"2021-12-31","expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974835,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on each of June 30, 2021, December 31, 2021, June 30, 2022, and December 31, 2022."}],"balance_after":35000,"derivative":{"exercise_price":2.86,"exercise_date":"2021-12-31","expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974834,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-09","kind":"sale","planned":true,"acquired":false,"shares":16790,"price":6.266,"value":105206.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The shares were sold in multiple transactions at prices ranging from $6.25 to $6.31. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974833,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-09","kind":"exercise","planned":true,"acquired":true,"shares":16790,"price":4.16,"value":69846.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":27996,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974832,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":6.002,"value":120040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974831,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":1.11,"value":22200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":31206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974830,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":35000,"price":6.019,"value":210665.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.08. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974829,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":35000,"price":2.11,"value":73850.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":46206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974828,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":5.946,"value":148650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The shares were sold in multiple transactions at prices ranging from $5.69 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974827,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":1.72,"value":43000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":36206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974826,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":5.962,"value":119240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The shares were sold in multiple transactions at prices ranging from $5.69 to $6.034. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974825,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":1.98,"value":39600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":31206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974824,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":5.962,"value":119240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The shares were sold in multiple transactions at prices ranging from $5.69 to $6.034. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974823,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":2.11,"value":42200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":31206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974822,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":35000,"price":5.95,"value":208250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The shares were sold in multiple transactions at prices ranging from $5.69 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974821,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":35000,"price":2.86,"value":100100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."}],"balance_after":46206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":974820,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:15:55.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":6.005,"value":24020.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11206,"source":{"system":"sec-edgar","filing":"0001133416-25-000061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000061/form4.xml","form_type":"4"}},{"id":1291017,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-01-30T17:40:26.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2025."}],"balance_after":60000,"derivative":{"exercise_price":1.23,"expiration_date":"2035-01-23","underlying":"comm Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-25-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000026/form4.xml","form_type":"4"}},{"id":1319973,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-12-31T12:45:05.000Z","date":"2024-12-30","kind":"purchase","planned":false,"acquired":true,"shares":6500,"price":1.16,"value":7540.0,"ownership":{"direct":true},"balance_after":15206,"source":{"system":"sec-edgar","filing":"0001133416-24-000074","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000074/form4.xml","form_type":"4"}},{"id":2042459,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-01-30T21:50:18.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2023."}],"balance_after":40000,"derivative":{"exercise_price":1.11,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-23-000030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000030/form4.xml","form_type":"4"}},{"id":2426938,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-01-25T21:52:52.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2022."}],"balance_after":40000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-22-000037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000037/form4.xml","form_type":"4"}},{"id":2769589,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:21.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results."}],"balance_after":70000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-21-013811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013811/doc4.xml","form_type":"4"}},{"id":2769588,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:21.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options vest 100% on March 31, 2022."}],"balance_after":40000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-013811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013811/doc4.xml","form_type":"4"}},{"id":3312685,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-01-13T22:56:48.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2020, December 31, 2020, June 30, 2021, and December 31, 2021."}],"balance_after":70000,"derivative":{"exercise_price":2.86,"expiration_date":"2030-01-09","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-20-001114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320001114/doc4.xml","form_type":"4"}},{"id":3500901,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-06-05T20:32:23.000Z","date":"2019-06-04","kind":"exercise","acquired":false,"shares":8706,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were originally issued on January 20, 2016 in a grant of 38,000 options which vested 25% upon grant and then approximately 792 options vested per month through January 2019."}],"balance_after":29294,"derivative":{"exercise_price":1.37,"expiration_date":"2026-01-20","underlying":"Common Stock","underlying_shares":8706},"source":{"system":"sec-edgar","filing":"0001179022-19-000039","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000039/edgar.xml","form_type":"4"}},{"id":3500900,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-06-05T20:32:23.000Z","date":"2019-06-04","kind":"exercise","acquired":true,"shares":8706,"price":1.37,"value":11927.22,"ownership":{"direct":true},"balance_after":8706,"source":{"system":"sec-edgar","filing":"0001179022-19-000039","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000039/edgar.xml","form_type":"4"}},{"id":3691954,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-01-18T22:16:22.000Z","date":"2019-01-16","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% on each of June 30, 2019, December 31, 2019, June 30, 2020, and December 31, 2020."}],"balance_after":70000,"derivative":{"exercise_price":4.72,"expiration_date":"2029-01-16","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001179022-19-000009","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000009/edgar.xml","form_type":"4"}},{"id":3890987,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-18T20:44:26.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% on June 30, 2018, 25% on September 30, 2018, and 50% on December 31, 2018."}],"balance_after":35000,"derivative":{"exercise_price":6.17,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001179022-18-000055","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000055/edgar.xml","form_type":"4"}},{"id":3894207,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-14T20:32:27.000Z","date":"2018-06-13","kind":"exercise","acquired":false,"shares":25544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on January 29, 2015, the grant date, with the remainder vesting ratably on a monthly basis over a three year period."}],"balance_after":12456,"derivative":{"exercise_price":3.45,"expiration_date":"2025-01-29","underlying":"Common Stock","underlying_shares":25544},"source":{"system":"sec-edgar","filing":"0001179022-18-000051","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000051/edgar.xml","form_type":"4"}},{"id":3894206,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-14T20:32:27.000Z","date":"2018-06-13","kind":"sale","acquired":false,"shares":30918,"price":7.7921,"value":240916.1478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold in multiple transactions at prices ranging from $6.52 to $8.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179022-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000051/edgar.xml","form_type":"4"}},{"id":3894205,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-14T20:32:27.000Z","date":"2018-06-13","kind":"exercise","acquired":true,"shares":25544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":30918,"source":{"system":"sec-edgar","filing":"0001179022-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000051/edgar.xml","form_type":"4"}},{"id":3894204,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-14T20:32:27.000Z","date":"2018-06-12","kind":"sale","acquired":false,"shares":12780,"price":6.5,"value":83070.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":5374,"source":{"system":"sec-edgar","filing":"0001179022-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000051/edgar.xml","form_type":"4"}},{"id":3897145,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-12T20:50:14.000Z","date":"2018-06-08","kind":"exercise","acquired":false,"shares":29294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period."}],"balance_after":8706,"derivative":{"exercise_price":1.37,"expiration_date":"2026-01-20","underlying":"Common Stock","underlying_shares":29294},"source":{"system":"sec-edgar","filing":"0001179022-18-000049","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000049/edgar.xml","form_type":"4"}},{"id":3897144,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-12T20:50:14.000Z","date":"2018-06-08","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":0,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001179022-18-000049","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000049/edgar.xml","form_type":"4"}},{"id":3897143,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-12T20:50:14.000Z","date":"2018-06-11","kind":"sale","acquired":false,"shares":10760,"price":6.5,"value":69940.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":18154,"source":{"system":"sec-edgar","filing":"0001179022-18-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000049/edgar.xml","form_type":"4"}},{"id":3897142,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-12T20:50:14.000Z","date":"2018-06-08","kind":"sale","acquired":false,"shares":104294,"price":5.7726,"value":602047.5444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $5.50 to $6.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":28914,"source":{"system":"sec-edgar","filing":"0001179022-18-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000049/edgar.xml","form_type":"4"}},{"id":3897141,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-12T20:50:14.000Z","date":"2018-06-08","kind":"exercise","acquired":true,"shares":29294,"price":1.37,"value":40132.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":184099,"source":{"system":"sec-edgar","filing":"0001179022-18-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000049/edgar.xml","form_type":"4"}},{"id":3897140,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-12T20:50:14.000Z","date":"2018-06-08","kind":"exercise","acquired":true,"shares":50000,"price":0.87,"value":43500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":103914,"source":{"system":"sec-edgar","filing":"0001179022-18-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000049/edgar.xml","form_type":"4"}},{"id":3900259,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-07","kind":"exercise","acquired":false,"shares":25701,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":50000,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":25701},"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3900258,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-07","kind":"exercise","acquired":false,"shares":75190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014."}],"balance_after":0,"derivative":{"exercise_price":2.32,"expiration_date":"2022-08-27","underlying":"Common Stock","underlying_shares":75190},"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3900257,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-06","kind":"exercise","acquired":false,"shares":4898,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":75701,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":4898},"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3900256,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-06","kind":"exercise","acquired":false,"shares":4180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014."}],"balance_after":75190,"derivative":{"exercise_price":2.32,"expiration_date":"2022-08-27","underlying":"Common Stock","underlying_shares":4180},"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3900255,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-07","kind":"sale","acquired":false,"shares":100891,"price":5.2063,"value":525268.8133,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $5.15 to $5.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":53914,"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3900254,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-07","kind":"exercise","acquired":true,"shares":25701,"price":0.87,"value":22359.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":154805,"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3900253,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-07","kind":"exercise","acquired":true,"shares":75190,"price":2.32,"value":174440.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":129104,"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3900252,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-06","kind":"sale","acquired":false,"shares":9078,"price":5.15,"value":46751.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":53914,"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3900251,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-06","kind":"exercise","acquired":true,"shares":4898,"price":0.87,"value":4261.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":62992,"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3900250,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-08T20:33:49.000Z","date":"2018-06-06","kind":"exercise","acquired":true,"shares":4180,"price":2.32,"value":9697.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":58094,"source":{"system":"sec-edgar","filing":"0001179022-18-000047","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000047/edgar.xml","form_type":"4"}},{"id":3903675,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-05","kind":"exercise","acquired":false,"shares":4294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":80599,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":4294},"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3903674,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-05","kind":"exercise","acquired":false,"shares":5630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014."}],"balance_after":79370,"derivative":{"exercise_price":2.32,"expiration_date":"2022-08-27","underlying":"Common Stock","underlying_shares":5630},"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3903673,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-04","kind":"exercise","acquired":false,"shares":5407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":84893,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":5407},"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3903672,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-04","kind":"exercise","acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014."}],"balance_after":85000,"derivative":{"exercise_price":2.32,"expiration_date":"2022-08-27","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3903671,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-05","kind":"sale","acquired":false,"shares":9924,"price":5.1575,"value":51183.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $5.15 to $5.18. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":53914,"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3903670,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-05","kind":"exercise","acquired":true,"shares":4294,"price":0.87,"value":3735.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":69338,"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3903669,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-05","kind":"exercise","acquired":true,"shares":5630,"price":2.32,"value":13061.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":65044,"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3903668,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-04","kind":"sale","acquired":false,"shares":10907,"price":5.1502,"value":56173.2314,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $5.15 to $5.16. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":53914,"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3903667,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-04","kind":"exercise","acquired":true,"shares":5407,"price":0.87,"value":4704.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":64821,"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3903666,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-06T20:31:06.000Z","date":"2018-06-04","kind":"exercise","acquired":true,"shares":5500,"price":2.32,"value":12760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":59414,"source":{"system":"sec-edgar","filing":"0001179022-18-000046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000046/edgar.xml","form_type":"4"}},{"id":3908728,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-04T20:51:59.000Z","date":"2018-06-01","kind":"exercise","acquired":false,"shares":59700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":90300,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":59700},"source":{"system":"sec-edgar","filing":"0001179022-18-000044","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000044/edgar.xml","form_type":"4"}},{"id":3908727,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-04T20:51:59.000Z","date":"2018-06-01","kind":"exercise","acquired":false,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014."}],"balance_after":90500,"derivative":{"exercise_price":2.32,"expiration_date":"2022-08-27","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001179022-18-000044","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000044/edgar.xml","form_type":"4"}},{"id":3908726,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-04T20:51:59.000Z","date":"2018-05-31","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014."}],"balance_after":100000,"derivative":{"exercise_price":2.32,"expiration_date":"2022-08-27","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001179022-18-000044","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000044/edgar.xml","form_type":"4"}},{"id":3908725,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-04T20:51:59.000Z","date":"2018-06-01","kind":"sale","acquired":false,"shares":69200,"price":5.1,"value":352920.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $5.00 to $5.18. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":53914,"source":{"system":"sec-edgar","filing":"0001179022-18-000044","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000044/edgar.xml","form_type":"4"}},{"id":3908724,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-04T20:51:59.000Z","date":"2018-06-01","kind":"exercise","acquired":true,"shares":59700,"price":0.87,"value":51939.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":123114,"source":{"system":"sec-edgar","filing":"0001179022-18-000044","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000044/edgar.xml","form_type":"4"}},{"id":3908723,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-04T20:51:59.000Z","date":"2018-06-01","kind":"exercise","acquired":true,"shares":9500,"price":2.32,"value":22040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":63414,"source":{"system":"sec-edgar","filing":"0001179022-18-000044","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000044/edgar.xml","form_type":"4"}},{"id":3908722,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-04T20:51:59.000Z","date":"2018-05-31","kind":"sale","acquired":false,"shares":50000,"price":5,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":53914,"source":{"system":"sec-edgar","filing":"0001179022-18-000044","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000044/edgar.xml","form_type":"4"}},{"id":3908721,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-04T20:51:59.000Z","date":"2018-05-31","kind":"exercise","acquired":true,"shares":50000,"price":2.32,"value":116000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018."}],"balance_after":103914,"source":{"system":"sec-edgar","filing":"0001179022-18-000044","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000044/edgar.xml","form_type":"4"}},{"id":3918921,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-05-24T20:50:50.000Z","date":"2018-05-22","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% on June 30, 2018, 25% on September30, 2018, and 50% on December 31, 2018."}],"balance_after":90000,"derivative":{"exercise_price":4.16,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001179022-18-000040","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000040/edgar.xml","form_type":"4"}},{"id":4098079,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-01-17T21:34:58.000Z","date":"2018-01-15","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% immediately, 25% on June 30, 2018, and 50% on December 31, 2018."}],"balance_after":90000,"derivative":{"exercise_price":5.87,"expiration_date":"2028-01-15","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001179022-18-000011","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000011/edgar.xml","form_type":"4"}},{"id":4531517,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":34538,"kind":"person","name":"Shlevin Harold H.","position":1,"cik":"0001557082","reported_name":"Shlevin Harold H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2016-12-06T22:10:29.000Z","date":"2016-12-03","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% immediately, 25% on July 1, 2017, and 50% on December 31, 2017."}],"balance_after":150000,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001179022-16-000124","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902216000124/edgar.xml","form_type":"4"}}]}